A Study of Isoprinosine in Patients With Severe AIDS

A Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Severe Acquired Immunodeficiency Syndrome

NCT00002295•Newport Pharmaceuticals International

View on ClinicalTrials.gov

Summary

To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to: Laboratory (immunologic defects): * Comparison of total helper and suppressor T-cell numbers among the groups. * Comparison of changes in natural killer cell activity. * Comparison of other laboratory findings among the groups. Clinical changes: * Comparison of the frequency of opportunistic infections among the groups. * Comparison of the frequency of the development of AIDS-related malignancies. * Comparison of other clinical manifestations relative to severity and time of onset.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Exclusion Criteria

•Co-existing Condition:
•Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer are excluded.
•Concurrent Medication:
•Excluded:
•Steroids.
•Cytotoxic immunosuppressive agents.
•Radiotherapy.
•The following are excluded:
•Critically ill patients.
•Patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy.
+6 more criteria

Locations (1)

Newport Pharmaceuticals International Inc

Laguna Hills, California, United States

Key Dates

Last Updated

June 24, 2005

Conditions

HIV Infections

Interventions

Inosine pranobex

DRUG

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Isoprinosine in Patients With Severe AIDS

Exclusion Criteria

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Skeletal Muscle Energetics and Fatiguability in Older Individuals

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

Comprehensive HIV and Harm Prevention Via Telehealth